Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Azurity Pharmaceuticals, Inc.
EIR
•Azurity Pharmaceuticals, Inc.•February 24, 2022

Azurity Pharmaceuticals, Inc. – FDA EIR, Feb 24, 2022

Record Details

An FDA inspection of Azurity Pharmaceuticals, Inc., located in Wilmington and Woburn, MA, took place from February 14 to February 24, 2022. This pre-announced inspection, initiated by the Division of Drug Quality II Compliance Branch under Compliance Program 7356.002A, focused on the company's manufacturing and distribution of non-sterile powder prescription compounding kits, including products such as Firvanq and FIRST Omeprazole. The regulatory framework aimed to ensure adherence to good manufacturing practices for these drug products. The inspection resulted in three main observations documented on a Form FDA 483. These issues included inadequate cleaning practices within the firm's sampling booth, evidenced by unknown powder residues; insufficient sampling procedures for bulk active pharmaceutical ingredients; and a failure to conduct periodic verification testing of the fill line cleaning processes. This latter observation was particularly critical as it occurred after the introduction of additional products to lines previously dedicated to single products, potentially impacting cleaning effectiveness. Azurity Pharmaceuticals is required to address these deficiencies by implementing comprehensive corrective and preventive actions to ensure ongoing compliance and maintain drug product quality.

Company
Azurity Pharmaceuticals, Inc.
Inspection date
February 24, 2022
Product type
drugs
Office
New England District Office
People
  • Erik W. Koester (Investigator)
  • Terry Bridgewater (Investigator)
View Company Profile

ID · 5a265872-1f81-4956-954b-5981dd871143

Violation Codes3
21 CFR 211.67(a)21 CFR 211.84(c)(4)21 CFR 211.67(b)(5)

Full citation text and observation details available on the Dashboard.

Other documents for Azurity Pharmaceuticals, Inc.
  • WARNING_LETTER - 2023-03-02March 2, 2023
  • EIR - 2019-07-26July 26, 2019
  • CRL
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Azurity Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.